Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean des ISR multicenter registry study [KISS])

Young Guk Ko, Jung Sun Kim, Byeong Keuk Kim, Donghoon Choi, Myeong Ki Hong, Dong Woon Jeon, Joo Young Yang, Young Keun Ahn, Myung Ho Jeong, Cheol Woong Yu, Kyeong Ho Yun, Do-Sun Lim, Yangsoo Jang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

There is currently no established standard treatment for in-stent restenosis (ISR) after the implantation of a drug-eluting stent (DES). The aim of this study was to investigate the efficacy of DES versus balloon angioplasty (BA) for the treatment of DES ISR in a multicenter registry cohort. After matching propensity scores of 805 patients with DES ISR treated with either DES (n = 422) or BA (n = 383), 268 matched pairs were selected and analyzed for major adverse cardiac events, a composite of death, myocardial infarction, and target-vessel revascularization, as the primary end point. Baseline clinical and lesion characteristics of the matched pairs were similar. Survival free of major adverse cardiac events at 2 years was higher with DES compared to BA (88.9% vs 78.7%, p <0.001), mainly because of higher TVR-free survival (92.4% vs 81.0%, p <0.001). Among various baseline variables, BA (hazard ratio 2.546, 95% confidence interval 1.412 to 4.593, p = 0.002) was the most important independent risk factor for recurrent target vessel revascularization, followed by acute coronary syndromes as the clinical presentation of DES ISR, and previous implantation of a sirolimus-eluting stent. Survival free of death, myocardial infarction, or stent thrombosis did not differ between the 2 groups. Whereas there was no significant difference in survival free of target vessel revascularization between DES and BA for focal ISR lesions, DES was superior to BA in diffuse ISR lesions (94.3% vs 75.2% at 2 years, p <0.001). In conclusion, compared to BA, the implantation of DES was safe and more effective in the treatment of DES ISR.

Original languageEnglish
Pages (from-to)607-613
Number of pages7
JournalAmerican Journal of Cardiology
Volume109
Issue number5
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

Drug-Eluting Stents
Multicenter Studies
Stents
Registries
Balloon Angioplasty
Survival
Myocardial Infarction
Propensity Score
Sirolimus
Acute Coronary Syndrome
Thrombosis
Therapeutics
Confidence Intervals

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean des ISR multicenter registry study [KISS]). / Ko, Young Guk; Kim, Jung Sun; Kim, Byeong Keuk; Choi, Donghoon; Hong, Myeong Ki; Jeon, Dong Woon; Yang, Joo Young; Ahn, Young Keun; Jeong, Myung Ho; Yu, Cheol Woong; Yun, Kyeong Ho; Lim, Do-Sun; Jang, Yangsoo.

In: American Journal of Cardiology, Vol. 109, No. 5, 01.03.2012, p. 607-613.

Research output: Contribution to journalArticle

Ko, Young Guk ; Kim, Jung Sun ; Kim, Byeong Keuk ; Choi, Donghoon ; Hong, Myeong Ki ; Jeon, Dong Woon ; Yang, Joo Young ; Ahn, Young Keun ; Jeong, Myung Ho ; Yu, Cheol Woong ; Yun, Kyeong Ho ; Lim, Do-Sun ; Jang, Yangsoo. / Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean des ISR multicenter registry study [KISS]). In: American Journal of Cardiology. 2012 ; Vol. 109, No. 5. pp. 607-613.
@article{22d70a164de3441ab58b99a25b184af5,
title = "Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean des ISR multicenter registry study [KISS])",
abstract = "There is currently no established standard treatment for in-stent restenosis (ISR) after the implantation of a drug-eluting stent (DES). The aim of this study was to investigate the efficacy of DES versus balloon angioplasty (BA) for the treatment of DES ISR in a multicenter registry cohort. After matching propensity scores of 805 patients with DES ISR treated with either DES (n = 422) or BA (n = 383), 268 matched pairs were selected and analyzed for major adverse cardiac events, a composite of death, myocardial infarction, and target-vessel revascularization, as the primary end point. Baseline clinical and lesion characteristics of the matched pairs were similar. Survival free of major adverse cardiac events at 2 years was higher with DES compared to BA (88.9{\%} vs 78.7{\%}, p <0.001), mainly because of higher TVR-free survival (92.4{\%} vs 81.0{\%}, p <0.001). Among various baseline variables, BA (hazard ratio 2.546, 95{\%} confidence interval 1.412 to 4.593, p = 0.002) was the most important independent risk factor for recurrent target vessel revascularization, followed by acute coronary syndromes as the clinical presentation of DES ISR, and previous implantation of a sirolimus-eluting stent. Survival free of death, myocardial infarction, or stent thrombosis did not differ between the 2 groups. Whereas there was no significant difference in survival free of target vessel revascularization between DES and BA for focal ISR lesions, DES was superior to BA in diffuse ISR lesions (94.3{\%} vs 75.2{\%} at 2 years, p <0.001). In conclusion, compared to BA, the implantation of DES was safe and more effective in the treatment of DES ISR.",
author = "Ko, {Young Guk} and Kim, {Jung Sun} and Kim, {Byeong Keuk} and Donghoon Choi and Hong, {Myeong Ki} and Jeon, {Dong Woon} and Yang, {Joo Young} and Ahn, {Young Keun} and Jeong, {Myung Ho} and Yu, {Cheol Woong} and Yun, {Kyeong Ho} and Do-Sun Lim and Yangsoo Jang",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.amjcard.2011.10.014",
language = "English",
volume = "109",
pages = "607--613",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean des ISR multicenter registry study [KISS])

AU - Ko, Young Guk

AU - Kim, Jung Sun

AU - Kim, Byeong Keuk

AU - Choi, Donghoon

AU - Hong, Myeong Ki

AU - Jeon, Dong Woon

AU - Yang, Joo Young

AU - Ahn, Young Keun

AU - Jeong, Myung Ho

AU - Yu, Cheol Woong

AU - Yun, Kyeong Ho

AU - Lim, Do-Sun

AU - Jang, Yangsoo

PY - 2012/3/1

Y1 - 2012/3/1

N2 - There is currently no established standard treatment for in-stent restenosis (ISR) after the implantation of a drug-eluting stent (DES). The aim of this study was to investigate the efficacy of DES versus balloon angioplasty (BA) for the treatment of DES ISR in a multicenter registry cohort. After matching propensity scores of 805 patients with DES ISR treated with either DES (n = 422) or BA (n = 383), 268 matched pairs were selected and analyzed for major adverse cardiac events, a composite of death, myocardial infarction, and target-vessel revascularization, as the primary end point. Baseline clinical and lesion characteristics of the matched pairs were similar. Survival free of major adverse cardiac events at 2 years was higher with DES compared to BA (88.9% vs 78.7%, p <0.001), mainly because of higher TVR-free survival (92.4% vs 81.0%, p <0.001). Among various baseline variables, BA (hazard ratio 2.546, 95% confidence interval 1.412 to 4.593, p = 0.002) was the most important independent risk factor for recurrent target vessel revascularization, followed by acute coronary syndromes as the clinical presentation of DES ISR, and previous implantation of a sirolimus-eluting stent. Survival free of death, myocardial infarction, or stent thrombosis did not differ between the 2 groups. Whereas there was no significant difference in survival free of target vessel revascularization between DES and BA for focal ISR lesions, DES was superior to BA in diffuse ISR lesions (94.3% vs 75.2% at 2 years, p <0.001). In conclusion, compared to BA, the implantation of DES was safe and more effective in the treatment of DES ISR.

AB - There is currently no established standard treatment for in-stent restenosis (ISR) after the implantation of a drug-eluting stent (DES). The aim of this study was to investigate the efficacy of DES versus balloon angioplasty (BA) for the treatment of DES ISR in a multicenter registry cohort. After matching propensity scores of 805 patients with DES ISR treated with either DES (n = 422) or BA (n = 383), 268 matched pairs were selected and analyzed for major adverse cardiac events, a composite of death, myocardial infarction, and target-vessel revascularization, as the primary end point. Baseline clinical and lesion characteristics of the matched pairs were similar. Survival free of major adverse cardiac events at 2 years was higher with DES compared to BA (88.9% vs 78.7%, p <0.001), mainly because of higher TVR-free survival (92.4% vs 81.0%, p <0.001). Among various baseline variables, BA (hazard ratio 2.546, 95% confidence interval 1.412 to 4.593, p = 0.002) was the most important independent risk factor for recurrent target vessel revascularization, followed by acute coronary syndromes as the clinical presentation of DES ISR, and previous implantation of a sirolimus-eluting stent. Survival free of death, myocardial infarction, or stent thrombosis did not differ between the 2 groups. Whereas there was no significant difference in survival free of target vessel revascularization between DES and BA for focal ISR lesions, DES was superior to BA in diffuse ISR lesions (94.3% vs 75.2% at 2 years, p <0.001). In conclusion, compared to BA, the implantation of DES was safe and more effective in the treatment of DES ISR.

UR - http://www.scopus.com/inward/record.url?scp=84857623932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857623932&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2011.10.014

DO - 10.1016/j.amjcard.2011.10.014

M3 - Article

C2 - 22172241

AN - SCOPUS:84857623932

VL - 109

SP - 607

EP - 613

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -